REGENXBIO Inc. — Director's Dealing 2017

Mar 29, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENXBIO Inc. (RGNX)
CIK: 0001590877
Period of Report: 2017-03-27

Reporting Person: Danos Olivier (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-27	Stock Option (Right to Buy)	$20.35	A	100000	Acquired	2027-03-26	Common Stock (100000)	Direct

Footnotes

F1: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 3/27/2018 while the optionee provides continuous service to the Issuer.